Who
Kamran Alam
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Taysha Gene Therapies; SVP - Finance & PFO, Rocket Pharmaceuticals.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $1.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Nov 2019
- Last trade
- 4 Feb 2026
- Last filed
- 6 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Feb 2026filed 6 Feb 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $7,4811,655 at $4.52 | filing |
| 4 Feb 2026filed 6 Feb 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $7,4811,655 at $4.52 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $110K23,849 at $4.61 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $110K23,849 at $4.61 | filing |
| 23 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $375K78,968 at $4.75 | filing |
| 23 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $375K78,968 at $4.75 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —359,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —231,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —231,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —359,000 at $0.00 | filing |
| 21 Aug 2025filed 22 Aug 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $155K54,491 at $2.85 | filing |
| 11 Mar 2025filed 13 Mar 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code F | $50K29,843 at $1.69 | filing |
| 2 Jan 2025filed 3 Jan 2025 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —431,000 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —431,000 at $0.00 | filing |
| 2 Feb 2024filed 6 Feb 2024 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code F | $1,9451,288 at $1.51 | filing |
| 2 Jan 2024filed 4 Jan 2024 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —590,413 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —590,413 at $0.00 | filing |
| 14 Dec 2023filed 18 Dec 2023 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —187,582 at $0.00 | filing |
| 24 Aug 2023filed 25 Aug 2023 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $77K33,000 at $2.33 | filing |
| 31 May 2023filed 10 Apr 2025 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,462 at $0.00 | filing |
News
Head-To-Head Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. MediWound (NASDAQ:MDWD)TSHA · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Kamran Alam; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.